New RNA drug takes aim at tough bladder cancer
NCT ID NCT06351904
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial is testing a new drug called RAG-01 in 72 people with a type of bladder cancer that has not responded to standard therapy. The drug uses a small RNA molecule to try to control the cancer. The main goals are to check safety and find the right dose, while also looking for early signs that it might work.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RAG-01 (a small activating RNA drug)
What this could lead to
If it works, this could point toward a new treatment option for bladder cancer patients who have not responded to standard therapy.
What could go wrong
This is an early Phase 1 trial with only 72 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to show benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON MUSCLE INVASIVE BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
GenesisCare North Shore
RECRUITINGSt Leonards, New South Wales, 2065, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peninsula & South Eastern Haematology and Oncology Group
RECRUITINGMelbourne, Victoria, 3199, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Royal Melbourne Hospital
RECRUITINGMelbourne, Victoria, 3050, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••